{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:47:58Z","timestamp":1786618078573,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":1614,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001159","name":"Hawaii Community Foundation","doi-asserted-by":"publisher","award":["HCF 09ADVC-45411"],"award-info":[{"award-number":["HCF 09ADVC-45411"]}],"id":[{"id":"10.13039\/100001159","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1074\/jbc.m115.710053","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T04:00:16Z","timestamp":1456286416000},"page":"8350-8362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death"],"prefix":"10.1016","volume":"291","author":[{"given":"Andr\u00e9 S.","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Opoku-Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannya R.","family":"Ibarra-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette P.","family":"Yco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Ambadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-en A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Pirrung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M115.710053_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"10.1074\/jbc.M115.710053_bib2","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1074\/jbc.M115.710053_bib3","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1074\/jbc.M115.710053_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1074\/jbc.M115.710053_bib5","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M115.710053_bib6","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1074\/jbc.M115.710053_bib7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M115.710053_bib8","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol"},{"key":"10.1074\/jbc.M115.710053_bib9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor \u03b1 response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J. Clin. Oncol"},{"key":"10.1074\/jbc.M115.710053_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2050-7771-1-13","article-title":"The resistance mechanisms of proteasome inhibitor bortezomib","volume":"1","author":"L\u00fc","year":"2013","journal-title":"Biomark. Res"},{"key":"10.1074\/jbc.M115.710053_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2184.2006.00402.x","article-title":"Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis","volume":"39","author":"Coleman","year":"2006","journal-title":"Cell Prolif"},{"key":"10.1074\/jbc.M115.710053_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nature06782","article-title":"A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism","volume":"452","author":"Groll","year":"2008","journal-title":"Nature"},{"key":"10.1074\/jbc.M115.710053_bib13","doi-asserted-by":"crossref","first-page":"6880","DOI":"10.1021\/bi300841r","article-title":"Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells","volume":"51","author":"Archer","year":"2012","journal-title":"Biochemistry"},{"key":"10.1074\/jbc.M115.710053_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bcp.2010.03.031","article-title":"Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt\/PKB activation in neuroblastoma","volume":"80","author":"Archer","year":"2010","journal-title":"Biochem. Pharmacol"},{"key":"10.1074\/jbc.M115.710053_bib15","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1073\/pnas.0901982106","article-title":"Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition","volume":"106","author":"Clerc","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M115.710053_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bcp.2011.06.031","article-title":"Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines","volume":"82","author":"Anshu","year":"2011","journal-title":"Biochem. Pharmacol"},{"key":"10.1074\/jbc.M115.710053_bib17","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cbic.200900411","article-title":"Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines","volume":"10","author":"Clerc","year":"2009","journal-title":"Chembiochem"},{"key":"10.1074\/jbc.M115.710053_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1039\/C0CC02238A","article-title":"The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity","volume":"47","author":"Clerc","year":"2011","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1074\/jbc.M115.710053_bib19","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/ejoc.201000317","article-title":"Convergent synthesis and biological evaluation of Syringolin A and derivatives as eukaryotic 20S proteasome inhibitors","volume":"2010","author":"Clerc","year":"2010","journal-title":"Eur. J. Org. Chem"},{"key":"10.1074\/jbc.M115.710053_bib20","doi-asserted-by":"crossref","first-page":"9950","DOI":"10.1016\/j.tet.2011.09.048","article-title":"Syntheses and cytotoxicity of syringolin B-based proteasome inhibitors","volume":"67","author":"Ibarra-Rivera","year":"2011","journal-title":"Tetrahedron"},{"key":"10.1074\/jbc.M115.710053_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/13880209.2011.626784","article-title":"Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma","volume":"50","author":"Opoku-Ansah","year":"2012","journal-title":"Pharm. Biol"},{"key":"10.1074\/jbc.M115.710053_bib22","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/ol100761z","article-title":"Total synthesis of syringolin A and B","volume":"12","author":"Pirrung","year":"2010","journal-title":"Org. Lett"},{"key":"10.1074\/jbc.M115.710053_bib23","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1002\/anie.201402428","article-title":"Total synthesis of syringolin A and improvement of its biological activity","volume":"53","author":"Chiba","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl"},{"key":"10.1074\/jbc.M115.710053_bib24","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2015.06.015","article-title":"Structure-activity relationship study of syringolin A as a potential anticancer agent","volume":"25","author":"Chiba","year":"2015","journal-title":"Bioorg Med. Chem. Lett"},{"key":"10.1074\/jbc.M115.710053_bib25","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1016\/j.bmc.2015.07.041","article-title":"Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines","volume":"23","author":"Totaro","year":"2015","journal-title":"Bioorg. Med. Chem"},{"key":"10.1074\/jbc.M115.710053_bib26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.chembiol.2014.04.010","article-title":"Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor","volume":"21","author":"Trivella","year":"2014","journal-title":"Chem. Biol"},{"key":"10.1074\/jbc.M115.710053_bib27","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem"},{"key":"10.1074\/jbc.M115.710053_bib28","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J. Comput. Chem"},{"key":"10.1074\/jbc.M115.710053_bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem"},{"key":"10.1074\/jbc.M115.710053_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1008763014207","article-title":"Combined molecular mechanical and continuum solvent approach (MM-PBSA\/GBSA) to predict ligand binding","volume":"18","author":"Massova","year":"2000","journal-title":"Perspect. Drug Discov. Des"},{"key":"10.1074\/jbc.M115.710053_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E","article-title":"Theory and applications of the generalized Born solvation model in macromolecular simulations","volume":"56","author":"Tsui","year":"2000","journal-title":"Biopolymers"},{"key":"10.1074\/jbc.M115.710053_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","article-title":"Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells","volume":"31","author":"Greenstein","year":"2003","journal-title":"Exp. Hematol"},{"key":"10.1074\/jbc.M115.710053_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1073\/pnas.0405495102","article-title":"The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma","volume":"102","author":"Slack","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M115.710053_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1074\/jbc.M115.710053_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0024-3205(95)00254-4","article-title":"In vivo cultivation of tumor cells in hollow fibers","volume":"57","author":"Hollingshead","year":"1995","journal-title":"Life Sci"},{"key":"10.1074\/jbc.M115.710053_bib36","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.7164\/antibiotics.41.1331","article-title":"Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity","volume":"41","author":"Oka","year":"1988","journal-title":"J. Antibiot"},{"key":"10.1074\/jbc.M115.710053_bib37","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.7164\/antibiotics.41.1812","article-title":"Chemical modification of the antitumor antibiotic glidobactin","volume":"41","author":"Oka","year":"1988","journal-title":"J. Antibiot"},{"key":"10.1074\/jbc.M115.710053_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1074\/jbc.M115.710053_bib39","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1021\/cr900019j","article-title":"Impact of natural products on developing new anti-cancer agents","volume":"109","author":"Cragg","year":"2009","journal-title":"Chem. Rev"},{"key":"10.1074\/jbc.M115.710053_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1074\/jbc.M115.710053_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cr0502504","article-title":"20S proteasome and its inhibitors: crystallographic knowledge for drug development","volume":"107","author":"Borissenko","year":"2007","journal-title":"Chem. Rev"},{"key":"10.1074\/jbc.M115.710053_bib42","doi-asserted-by":"crossref","first-page":"11653","DOI":"10.1523\/JNEUROSCI.23-37-11653.2003","article-title":"Neuronal induction of the immunoproteasome in Huntington's disease","volume":"23","author":"D\u00edaz-Hern\u00e1ndez","year":"2003","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M115.710053_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neurobiolaging.2004.12.004","article-title":"Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains","volume":"27","author":"Mishto","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1074\/jbc.M115.710053_bib44","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.febslet.2007.01.061","article-title":"Transformation of the proteasome with age-related macular degeneration","volume":"581","author":"Ethen","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1074\/jbc.M115.710053_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10350-006-0796-7","article-title":"Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease","volume":"50","author":"Fitzpatrick","year":"2007","journal-title":"Dis. Colon Rectum"},{"key":"10.1074\/jbc.M115.710053_bib46","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1172\/JCI28804","article-title":"Proteasome-mediated degradation of I\u03baB\u03b1 and processing of p105 in Crohn disease and ulcerative colitis","volume":"116","author":"Visekruna","year":"2006","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M115.710053_bib47","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/art.21782","article-title":"Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren's syndrome","volume":"54","author":"Egerer","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002192582041141X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002192582041141X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M115.710053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T11:04:37Z","timestamp":1641294277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002192582041141X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":47,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S002192582041141X"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m115.710053","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.M115.710053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}